Blood Cancers
Advertisement
Area Deprivation Index was associated with overall survival in both Black and Hispanic patients.
Black, Hispanic, and Asian patients were underrepresented in trials compared with national lymphoma data.
Families reported the direct cash support program offered them the “ability to spend more time at their child’s ...
Despite delays to infusion, response rates to CAR-T were comparable across racial groups.
The proportion of myeloma cases linked to BMI and diabetes was higher in Black patients than White patients.
Patients who were Black or female were more likely to refuse treatment for multiple myeloma.
Researchers found that Hispanic people were more likely to develop and die from ALL than Black and White people.
Hispanic patients with multiple myeloma had lower overall response rates to idecabtagene vicleucel.
Advanced age, financial constraints contribute to higher discontinuation rates among elderly Medicare beneficiaries.
Breastfeeding has a protective effect against acute lymphoblastic leukemia in young children.
Study suggests significant associations between nonchromosomal birth defects and childhood leukemia.
Vitamin C and D supplementation for the treatment of AML, was associated with reduced infection rates.
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
The prognosis for induction failure in childhood T-cell ALL remains unfavorable despite advancements in treatment.
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.